The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review
The Journal of Infectious Diseases · 16.08.2024 · 230 (2) · e496-e502
DOI: 10.1093/infdis/jiad519 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 22.11.2023. Verfasst von Anthony M Marchese und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Affairs, Novavax, Inc, Gaithersburg, Maryland. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Immunization, Secondary. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ashfield MedComms, Inizio company, Novavax, Inc.
Abstract (Originalsprache)
Coronavirus disease 2019 (COVID-19) continues to be a global health concern, and booster doses are necessary for maintaining vaccine-mediated protection, limiting the spread of severe acute respiratory syndrome coronavirus 2. Despite multiple COVID-19 vaccine options, global booster uptake remains low. Reactogenicity, the occurrence of adverse local/systemic side effects, plays a crucial role in vaccine uptake and acceptance, particularly for booster doses. We conducted a targeted review of the reactogenicity of authorized/approved messenger RNA (mRNA) and protein-based vaccines demonstrated by clinical trials and real-world evidence. It was found that mRNA-based boosters show a higher incidence and an increased severity of reactogenicity compared with the Novavax protein-based COVID-19 vaccine (NVX-CoV2373). In a recent study from the National Institute of Allergy and Infectious Diseases, the incidence of pain/tenderness, swelling, erythema, fatigue/malaise, headache, muscle pain, or fever was higher in individuals boosted with BNT162b2 (0.4% to 41.6% absolute increase) or mRNA-1273 (5.5% to 55.0% absolute increase) compared with NVX-CoV2373. Evidence suggests that NVX-CoV2373, when utilized as a heterologous booster, demonstrates less reactogenicity compared with mRNA vaccines, which, if communicated to hesitant individuals, may strengthen booster uptake rates worldwide. Clinical Trials Registration NCT04889209.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Affairs, Novavax, Inc, Gaithersburg, Maryland.
- Department of Molecular Genetics, University of Toronto, Canada.
ORCID-Profile: Anthony M Marchese
Förderung
- Ashfield MedComms
- Inizio company
- Novavax, Inc
Zitieren
APA
Marchese, A. M., Rousculp, M., Macbeth, J., Beyhaghi, H., Seet, B. T., & Toback, S. (2024). The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review. The Journal of Infectious Diseases, 230(2), e496-e502. https://doi.org/10.1093/infdis/jiad519
Vancouver
Marchese AM, Rousculp M, Macbeth J, Beyhaghi H, Seet BT, Toback S. The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review. The Journal of Infectious Diseases. 2024;230(2):e496-e502. doi:10.1093/infdis/jiad519
BibTeX
@article{Marchese2024,
author = {Marchese, Anthony M and Rousculp, Matthew and Macbeth, John and Beyhaghi, Hadi and Seet, Bruce T and Toback, Seth},
title = {The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {230},
number = {2},
pages = {e496--e502},
doi = {10.1093/infdis/jiad519}
}
EUVIMED